Eli Lilly Weight Loss Pill Shows Better Results Than Injectable Competitors In Phase 3 Trial
Eli Lilly Weight Loss Pill Shows Better Results Than Injectable Competitors In Phase 3 Trial: the analysis positions LLY, AMZN and CAH to benefit and ALT, BDX and HIMS under pressure; confidence medium.
Analyzed 2026-08-18 — point-in-time, never revised. Outcomes are scored against SPY and published either way.
Ranked exposures
- ▼ ALT Altimmune, Inc. — confidence medium
Lilly’s highly effective obesity pill could reduce the appeal and differentiation of Altimmune’s injectable pemvidutide and other next-generation injectable obesity treatments. - ▼ BDX Becton, Dickinson and Company — confidence medium
Rising adoption of oral obesity drugs could modestly weaken long-term demand for GLP-1 injection devices, pen needles, prefilled syringes, and related supplies. - ▼ HIMS Hims & Hers Health, Inc. — confidence medium
Lilly’s convenient branded oral GLP-1 could erode demand for Hims & Hers’ compounded injectable offerings, threatening a key growth driver. - ▼ NVO Novo Nordisk A/S — confidence medium
Lilly’s superior oral weight-loss pill could erode Novo Nordisk’s injectable and oral GLP-1 market share by offering greater efficacy with greater convenience. - ▼ VKTX Viking Therapeutics, Inc. — confidence medium
Lilly’s effective oral obesity therapy raises competitive and efficacy hurdles for Viking, whose injectable-focused pipeline faces a formidable first-mover rival. - ▼ WST West Pharmaceutical Services, Inc. — confidence medium
A shift from injectable obesity treatments to pills could modestly reduce long-term demand for elastomer components, stoppers, and self-injection packaging and delivery systems. - ▼ AMGN Amgen Inc. — confidence low
Amgen's injectable MariTide obesity candidate may face increased commercialization and differentiation risk from a stronger oral Lilly competitor. - ▼ GPCR Structure Therapeutics Inc. — confidence low
Lilly's superior oral data compresses the commercial opportunity and partnership value for Structure's small-molecule GLP-1. - ▼ HSY The Hershey Company — confidence low
Broader, cheaper access to appetite-suppressing pills threatens confectionery and impulse snack volumes. - ▼ MDLZ Mondelez International, Inc. — confidence low
Mass adoption of a convenient oral weight-loss drug pressures long-term demand for cookies, crackers and indulgent snacks. - ▼ PFE Pfizer Inc. — confidence low
Pfizer's efforts to develop an oral obesity treatment would be disadvantaged if Lilly establishes an efficacy lead and gains first-mover momentum in the pill segment. - ▲ LLY Eli Lilly and Company — confidence medium
Superior Phase 3 results for Lilly’s oral obesity pill could expand adoption beyond injections, strengthen its franchise, and increase share in the vast obesity market. - ▲ AMZN Amazon.com, Inc. — confidence low
Amazon Pharmacy and its direct-to-consumer fulfillment partnerships gain from mail-order-friendly oral obesity medication demand. - ▲ CAH Cardinal Health, Inc. — confidence low
Benefits from expanded branded pharmaceutical distribution volumes as an easy-to-ship pill scales faster than cold-chain injectables. - ▲ COR Cencora, Inc. — confidence low
Pharmaceutical distributors earn fees on rising branded specialty and oral obesity drug volumes flowing through their networks. - ▲ CVS CVS Health Corporation — confidence low
Higher-volume oral obesity prescriptions drive retail pharmacy scripts and Caremark PBM rebate/formulary economics. - ▲ MCK McKesson Corporation — confidence low
Massive incremental oral GLP-1 script volume boosts distribution throughput and profits. - ▲ TDOC Teladoc Health, Inc. — confidence low
Telehealth weight-management programs gain more prescribing volume and members from a widely accessible oral obesity drug. - ▲ TMO Thermo Fisher Scientific Inc. — confidence low
Small-molecule API and oral solid-dose manufacturing capacity demand rises as pill-based obesity therapies scale to tens of millions of patients. - ▲ UNH UnitedHealth Group Incorporated — confidence low
A lower-cost oral alternative to expensive injectables could ease pharmacy benefit cost trend while improving members' metabolic health outcomes.
What happened
| Horizon | Verdict | Top pick | Excess vs SPY |
|---|---|---|---|
| 1 trading days | Right | LLY | +4.3% vs SPY |
| 5 trading days | Mixed | LLY | +6.6% vs SPY |
| 30 trading days | Mixed | LLY | +1.2% vs SPY |
More
Related scenarios
- Iranian Guards say two tankers hit mines in Hormuz
- PetroChina set for record trading profit as war upends markets
- Ascendis Pharma receives positive CHMP opinion for TransCon CNP
- ◇ What if… Bitcoin dips to $77,500 in October
Stocks in this scenario
ALT · BDX · HIMS · NVO · VKTX · WST · AMGN · GPCR · HSY · MDLZ · PFE · LLY · AMZN · CAH · COR · CVS · MCK · TDOC · TMO · UNH
News events · All scenarios · Pricing · Track record · Methodology · Map your own scenario